CG Oncology Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
CG Oncology Inc. is a clinical biopharmaceutical company focused on bladder cancer, with an emphasis on bladder-sparing therapies for patients with non-muscle invasive disease. The company’s lead product candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy designed to act directly within the bladder and engage the immune system against tumors. CG Oncology is developing this therapy across multiple current clinical programs for high-risk and intermediate-risk bladder cancer settings, including combination studies with other oncology treatments. The company’s work centers on addressing unmet needs in urologic oncology through localized treatment approaches that aim to preserve the bladder while targeting disease at the source.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Arthur Kuan
- Employees
- 142
- Headquarters
- Dallas, TX, United States
- Website
- cgoncology.com